Evidence map›Paper›PMID 15047832›Full record

ArticleJournal of virology2004

Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions.

Xiaoming Liu, Ziying Yan, Meihui Luo, Roman Zak, Ziyi Li, Ryan R Driskell, Yumao Huang, Nam Tran, John F Engelhardt

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Analysis of adeno-associated virus progenitor cell transduction in mouse lung.Molecular therapy : the journal of the American Society of Gene Therapy · 2009
    Article
  12. Recombinant adeno-associated virus transduction and integration.Molecular therapy : the journal of the American Society of Gene Therapy · 2008
    Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiaoming LiuDepartment of Anatomy and Cell Biology and the Center for Gene Therapy of Cystic Fibrosis and Other Genetic Diseases, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.
Ziying Yan
Meihui Luo
Roman Zak
Ziyi Li
Ryan R Driskell
Yumao Huang
Nam Tran
John F Engelhardt
University of Iowa · US

Funding

Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Alejandro Antonio Pezzulo · 1998 to 2026
$30.5M
Xylitol Enhancement of Bacterial Killing by AirwayP50HL061234 · NHLBI · UNIVERSITY OF IOWA · PI ZABNER, JOSEPH · 1998 to 2007
$13.6M
MECHANISMS OF RAAV TRANSDUCTION IN THE AIRWAYR01HL058340 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI ENGELHARDT, JOHN F · 1996 to 2008
$3.0M
NHLBI NIH HHS P50 HL061234NHLBI NIH HHS P50 HL61234NHLBI NIH HHS R01 HL058340NHLBI NIH HHS R01 HL58340NIDDK NIH HHS P30 DK054759NIDDK NIH HHS P30 DK54759
6 · The paper itself

Abstract

Recombinant adeno-associated virus (rAAV) vectors possess the unique ability to introduce genetic alterations at sites of homology in genomic DNA through a mechanism thought to predominantly involve homologous recombination. We have investigated the efficiency of this approach using a mutant enhanced green fluorescent protein (eGFP) fluorescence recovery assay that facilitates detection of gene correction events in living cells under nonselective conditions. Our data demonstrate that rAAV infection can correct a mutant eGFP transgene at an efficiency of 0.1% in 293 cells, as determined by fluorescence-activated cell-sorting analysis. Gene repair was also confirmed using clonal expansion of GFP-positive cells and sequencing of the eGFP transgene. These results support previous findings demonstrating the efficacy of rAAV for gene targeting. In an effort to improve gene-targeting efficiencies, we evaluated several agents known to increase rAAV transduction (i.e., expression of an expressed gene), including genotoxic stress and proteasome inhibitors, but observed no correlation between the level of gene repair and rAAV transduction. Interestingly, however, our results demonstrated that enrichment of G(1)/S-phase cells in the target population through the addition of thymidine moderately (approximately 2-fold) increased gene correction compared to cells in other cell cycle phases, including G(0)/G1, G(1), and G(2)/M. These results suggest that the S phase of the cell cycle may more efficiently facilitate gene repair by rAAV. Transgenic mice expressing the mutant GFP were used to evaluate rAAV targeting efficiencies in primary fetal fibroblast and tibialis muscles. However, targeting efficiencies in primary mouse fetal fibroblasts were significantly lower (approximately 0.006%) than in 293 cells, and no correction was seen in tibialis muscles following rAAV infection. To evaluate the molecular structures of rAAV genomes that might be responsible for gene repair, single-cell injection studies were performed with purified viral DNA in a mutant eGFP target cell line. However, the failure of direct cytoplasm- or nucleus-injected rAAV DNA to facilitate gene repair suggests that some aspect of intracellular viral processing may be required to prime recombinant viral genomes for gene repair events.

Indexed as

Gene TargetingGenetic VectorsPoint MutationAnimalsBase SequenceCell LineDependovirusDNA, RecombinantDNA RepairGreen Fluorescent ProteinsHumansLuminescent ProteinsMiceMice, TransgenicModels, GeneticRecombinant ProteinsDNA, RecombinantGreen Fluorescent ProteinsLuminescent ProteinsRecombinant Proteins

Identifiers

PMID15047832
PMCPMC374254
OpenAlexW2141449954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.